RhumbLine Advisers’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.1M | Buy |
73,168
+17,145
| +31% | +$257K | ﹤0.01% | 2198 |
|
|
2025
Q1 | $904K | Sell |
56,023
-1,634
| -3% | -$26.4K | ﹤0.01% | 2223 |
|
|
2024
Q4 | $1.34M | Buy |
57,657
+3,722
| +7% | +$86.6K | ﹤0.01% | 2091 |
|
|
2024
Q3 | $1.59M | Buy |
53,935
+2,039
| +4% | +$60K | ﹤0.01% | 2027 |
|
|
2024
Q2 | $1.22M | Buy |
+51,896
| New | +$1.22M | ﹤0.01% | 2140 |
|
|
2022
Q2 | – | Sell |
-1,957
| Closed | -$113K | – | 3231 |
|
|
2022
Q1 | $113K | Sell |
1,957
-200
| -9% | -$11.5K | ﹤0.01% | 2868 |
|
|
2021
Q4 | $256K | Sell |
2,157
-9
| -0.4% | -$1.07K | ﹤0.01% | 2758 |
|
|
2021
Q3 | $430K | Buy |
2,166
+59
| +3% | +$11.7K | ﹤0.01% | 2615 |
|
|
2021
Q2 | $367K | Buy |
2,107
+254
| +14% | +$44.2K | ﹤0.01% | 2706 |
|
|
2021
Q1 | $367K | Sell |
1,853
-135
| -7% | -$26.7K | ﹤0.01% | 2627 |
|
|
2020
Q4 | $391K | Buy |
1,988
+175
| +10% | +$34.4K | ﹤0.01% | 2544 |
|
|
2020
Q3 | $321K | Sell |
1,813
-248
| -12% | -$43.9K | ﹤0.01% | 2488 |
|
|
2020
Q2 | $477K | Buy |
2,061
+543
| +36% | +$126K | ﹤0.01% | 2365 |
|
|
2020
Q1 | $177K | Buy |
1,518
+19
| +1% | +$2.22K | ﹤0.01% | 2628 |
|
|
2019
Q4 | $286K | Buy |
1,499
+7
| +0.5% | +$1.34K | ﹤0.01% | 2618 |
|
|
2019
Q3 | $287K | Buy |
1,492
+117
| +9% | +$22.5K | ﹤0.01% | 2600 |
|
|
2019
Q2 | $235K | Buy |
1,375
+410
| +42% | +$70.1K | ﹤0.01% | 2725 |
|
|
2019
Q1 | $194K | Buy |
965
+102
| +12% | +$20.5K | ﹤0.01% | 2754 |
|
|
2018
Q4 | $162K | Buy |
863
+283
| +49% | +$53.1K | ﹤0.01% | 2795 |
|
|
2018
Q3 | $139K | Sell |
580
-29
| -5% | -$6.95K | ﹤0.01% | 2816 |
|
|
2018
Q2 | $161K | Buy |
+609
| New | +$161K | ﹤0.01% | 2790 |
|